Silence
Cancer
A Partner-Ready, Receptor-Targeted Peptide ASO Platform designed to Selectively Silence high value, Hard to Drug Cancer Genes with early In Vivo Studies reporting No Observed Organ Toxicity.
Extra-Hepatic Delivery
Peptide-guided targeting reaches solid tumors beyond the liver — where GalNAc and LNP platforms cannot
In Vivo Proof of Concept
KOP-101 PC3 xenograft study
Targeted Genomic Messenger — A Modular ASO Delivery Engine
KOP is developing a versatile, tumour-targeted delivery platform designed to power multiple nucleic-acid therapeutics including siRNA, antisense oligonucleotides and mRNA therapeutics. Rather than relying on a single drug candidate, KOP's modular platform supports a diversified pipeline across multiple cancer targets and therapeutic modalities creating the potential for broader applications, strategic partnerships, multiple licensing opportunities, and scalable long-term value.
KOP: The Delivery Engine Behind the Next Generation of Precision Oncology
One platform. Multiple payloads.
Unlimited oncology targets.
Multi-Payload Capability
The TGM platform is not locked to a single therapeutic class. siRNA, ASO, mRNA, and potentially CRISPR-based payloads can all be delivered through the same tumour-targeted carrier — one engine, many medicines.
Receptor-Targeted Precision Delivery
A tumour-selective peptide carrier binds receptors overexpressed on cancer cells, enabling active intracellular uptake, bypassing the liver-first limitations of GalNAc and LNP platforms to reach solid tumours directly.
Diversified Pipeline & Licensing Value
The modular architecture enables rapid expansion across oncogene targets and tumour types without platform redesign — creating multiple licensing opportunities, partnership pathways, and a capital-efficient route to scale.
Why KOP's Approach Is Different
Existing RNA delivery platforms are constrained by liver-first biodistribution. KOP's peptide-guided ASO platform is engineered for solid tumors.
GalNAc Conjugates
Liver-restricted delivery only
Hepatocyte-selective — cannot reach solid tumors in prostate, breast, brain, or ovarian tissue
LNP / Lipid Nanoparticles
Systemic toxicity & immunogenicity
Inflammatory responses and off-target organ accumulation limit repeat dosing and solid tumor access
KOP TGM Platform
Tumor-selective. Extra-hepatic.
Peptide carrier actively targets receptors overexpressed on cancer cells — enabling intracellular ASO delivery with no observed toxicity
A Delivery Platform Built for the Next Generation of Nucleic-Acid Medicine.
KOP's Targeted Genomic Messenger (TGM) platform is engineered to solve the fundamental challenge in nucleic-acid therapeutics: getting the payload inside the right cell. By pairing a tumour-selective peptide carrier with interchangeable nucleic-acid payloads — ASO, siRNA, mRNA, or potentially CRISPR-based constructs — KOP achieves active intracellular delivery to solid tumours without relying on liver-targeted vectors like GalNAc or LNP.
Extra-Hepatic Solid Tumour Targeting
The peptide carrier binds receptors overexpressed on cancer cells, enabling receptor-mediated endocytosis directly into the tumour — reaching tissues that GalNAc and LNP platforms cannot.
Interchangeable Payload Architecture
The same delivery vehicle supports multiple therapeutic classes. Swapping the nucleic-acid payload — ASO, siRNA, mRNA, or CRISPR — does not require redesigning the platform, enabling rapid pipeline expansion across targets and tumour types.
No Observed Organ Toxicity in Early In Vivo Work
Preclinical in vivo studies to date have shown no observed toxicity to healthy organs — a key differentiator for a delivery platform designed for systemic administration.
Pipeline Reach
One delivery engine. Four solid tumour programs. Each built on the same TGM platform — expandable across targets and payload classes.
Research Partners & Collaborators
World-Class Scientific Team
Tibor Gajdics
President, CEO & Chairman
View More
Dr. Mathew L. Thakur
Scientific Advisory Board Member
View More
Leigh Berryman
Executive Fractional Director of Development
View More
Sylvie Quenneville
VP of Strategic Development & Corporate Affairs
View More
Marco Strub
Director
View More
Aziz-Ur Rehman
Chief Financial Controller
View More
Dr. Jamal Daoud, PhD
Scientific Advisory Board Member
View More
Dr. Emma S. Guns
Past Scientific Advisory Board Member
View More
Four Pillars of Differentiated Value
KOP Therapeutics is developing a differentiated precision-oncology platform designed to deliver gene-silencing therapeutics directly to cancer cells. By combining targeted delivery, modular payload flexibility, a favourable early safety profile, and a scalable development strategy, KOP aims to unlock the therapeutic potential of RNA-based medicines across multiple cancer indications.
Science
KOP's proprietary delivery platform combines a tumour-targeting peptide with therapeutic olignonucleotides designed to enter tumour cells and silence cancer-driving genes. It's modular design may support multiple payloads and cancer targets while limiting exposure to healthy tissue.
Safety
KOP's tumour-directed approach is designed to concentrate therapeutic activity within cancer cells while minimizing exposure to healthy tissue. Early preclinical studies have demonstrated anti-tumour activity without observed systemic toxicity, supporting the potential for an improved therapeutic window compared with less-targeted treatment approaches.
Scalability
KOP is building a modular, plug-and-play delivery platform capable of supporting multiple nucleic-acid payloads, including antisense oligonucleotides, siRNA, mRNA therapeutics and potentially gene-editing technologies. This flexibility creates opportunities to generate multiple therapeutic candidates, expand across cancer indications and establish strategic partnerships around a common delivery engine.
Validation
KOP's technology is supported by a growing body of scientific and preclinical evidence, including tumour-targeting confirmation, gene knockdown, cancer-cell killing and in-vivo anti-tumour activity. Ongoing third-party studies, human-tissue testing and collaborations with recognized research and development partners are designed to further validate the platform and advance lead candidates toward clinical development.
Ready to explore a partnership or investment opportunity?
Connect With Our Corporate Team
We welcome inquiries from investors, research partners, oncology professionals, and the media. Our corporate development team responds within one business day.
PRESIDENT & CEO
Tibor Gajdics
PHONE
604.771.8332HEADQUARTERS
Vancouver, British Columbia, Canada & Montreal, Quebec, Canada